Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: a systematic review

BACKGROUND: Osimertinib, the third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has become the standard treatment in cases where rebiopsy reveals T790M mutation after the first-line EGFR-TKI treatment. However, the prognosis of patients after rebiopsy, the most i...

Descripción completa

Detalles Bibliográficos
Autores principales: Imakita, Takuma, Matsumoto, Hirotaka, Hirano, Katsuya, Morisawa, Toshiyuki, Sakurai, Azusa, Kataoka, Yuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346502/
https://www.ncbi.nlm.nih.gov/pubmed/30683066
http://dx.doi.org/10.1186/s12885-019-5309-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346502/
https://www.ncbi.nlm.nih.gov/pubmed/30683066
http://dx.doi.org/10.1186/s12885-019-5309-x

Ejemplares similares